European early-stage start-up investment stays resilient despite overall fall in funding

08 Jun 2023 | News byte

NB1
Data is as of 15 May 2023, with H1 figures extrapolated linearly. Excludes the following: biotech, secondary transactions, debt, lending capital and grants. Source: Atomico (powered by Dealroom.co and Crunchbase)


Global investment in start-ups has dropped off hugely in the past year after a peak in 2021, but there are still reasons for optimism in Europe, a new report from European venture capital firm Atomico shows.

One basis for that is the resilience of early-stage funding rounds worth below $15 million. While there has been a decrease since 2021 and 2022, the first half of 2023 is on track to be the third best year on record for early-stage investments.

Data from Atomico’s State of European Tech report shows that early-stage funding in the first half of this year is down 21% from the first half of 2022, from $10.3 billion to $8.2 billion, but it is still higher than the years before 2021.

Much of the slowdown in investment is coming from a big drop off in later-stage funding.

Atomico describes this as a return to long-term averages, with 2021 and to some extent 2022 being outliers. This is seen as an opportunity to build healthier ecosystem, with a clearer focus on quality. In the short-term, there will be fewer companies started, but the ones that break through will more likely be winners, with a strong foundation of senior talent and greater share of the region’s resources, the analysis says.

Start-up investment is projected to reach $51 billion in Europe by the end of this year, That compares to $38 billion in 2020.

This outlook is much more positive than the one portrayed in the recent Global Startup Ecosystem Index by StartupBlink, which described the fall in start-up investment as the world entering into “a winter period in start-up funding”. 

Graph1
Data is as of 14 May, with May total extrapolated based on first half of the month data. Full year extrapolated based on year-to-date data. Excludes the following: biotech, secondary transactions, debt, lending capital and grants. Source: Atomico (powered by Dealroom.co and Crunchbase)

Never miss an update from Science|Business:   Newsletter sign-up